Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global $2.85 Bn Chronic Idiopathic Constipation (CIC) Drugs Market to 2025 - Research and Markets

Research and Markets
Posted on: 19 Sep 17

The "Global Chronic Idiopathic Constipation (CIC) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.

The chronic idiopathic constipation drugs market was valued at USD 1889.85 Mn in 2017, and is expected to reach USD 2857.45 Mn by 2025, expanding at a CAGR of 6.4% from 2017 - 2025.

Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation - CIC are the major factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global market during forecast period.

In terms of market segmentation by drug type, Lubiprostone drugs segment currently dominates the market. However, the segment due to its relatively lower efficacy, patent loss and growing competition from Linaclotide will lose its dominance in the upcoming future. The Linaclotide drugs market for CIC treatment is anticipated to grow at a CAGR of 7.7% during 2017 - 2025.

Analyzing the symptoms, constipation is not considered as a disease but a condition, side effect or syndrome. This factor greatly contributes to the lesser visits from patients to address the issue. Thus over 65% of the CIC drugs market is captured by OTC drugs segment. The OTC market is expected to continue to dominate the market at a CAGR of 6.6% during 2017 - 2025.

The CIC drugs market is currently open for further research and development and thus introduction of novel pharmaceutical solutions. Actavis, Chugai Pharmaceutical, Ferrin International, Synergy Pharmaceuticals and others are among the top payers active in the global chronic idiopathic constipation drugs market.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Global CIC Drugs Market Analysis

Chapter 4 Global CIC Drugs Market, by Drug Type

Chapter 5 Global CIC Drugs Market, by Prescription Type

Chapter 6 Global CIC Drugs Market, by Geography

Chapter 7 Company Profiles

  • Actavis
  • Chugai Pharmaceutical
  • Ferring International Center S.A.
  • Synergy Pharmaceuticals
  • Pfizer
  • GlaxoSmithKline
  • Roche Holding AG
  • Sanofi
  • Bayer AG
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals Inc
  • Ironwood Pharmaceuticals inc
  • Progenics pharmaceuticals inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 19/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.